Research ArticleDelivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes
Graphical Abstract
siRNA-loaded liposome targeted by phage protein fused with a MCF-7 cell-specific peptide DMPGTVLP. The hydrophobic helix of the protein is anchored in the lipid bilayer, whereas the N-terminal fusion peptide DMPGTVLP is displayed on the surface of the liposome. The siRNA molecules are pictured as strands inside the liposomes.
Section snippets
Reagents
L-α-phosphatidylcholine (ePC); 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (sodium salt; DPPG); 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt; DOTAP); 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethyleneglycol)2000] (ammonium salt; PEG2000-PE ); and cholesterol (CHOL) were from Avanti Polar Lipids Inc. (Alabaster, Alabama).
Sodium cholate, 2.5% CHAPS: 3-[(3-cholamidopropyl)dimethylammonio]-1-proanesulfonate, bovine serum albumin (BSA), phenylmethanesulfonyl
Selection of breast cancer cell-specific phages
To obtain MCF-7 breast cancer cell-binding phages, the billion-clone library of phages harboring 8- mer peptides on all 4,000 copies of major coat proteins27 was used for in vitro selection. A portion of the library containing 100 billion phage particles was depleted first for phages binding a cell culture flask and then was applied to MCF-7 cells. Unbound phages were removed, whereas bound phages were eluted with mild acid. The eluted phages were amplified, purified and used in subsequent
Discussion
To enhance a potential anticancer efficiency of liposome-encapsulated siRNAs, we specifically targeted them via fusion with preselected phage protein specific for cancer cells MCF-7. To simplify the procedure and exclude any chemical conjugation reactions, we used spontaneous insertion of the phage proteins and siRNA into parental liposomes, followed by their fusion in mild conditions. The tumor-specific protein was isolated from the phage that was affinity selected from multibillion-clone
References (35)
- et al.
Strategies for targeted nonviral delivery of siRNAs in vivo
Trends Mol Med
(2009) - et al.
A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation
Blood
(2009) - et al.
Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA
Mol Ther
(2008) - et al.
Landscape phage fusion protein-mediated targeting of nanomedicines enhances their prostate tumor cell association and cytotoxic efficiency
Nanomedicine
(2010) - et al.
Liposomes targeted by fusion phage proteins
Nanomedicine
(2009) - et al.
Display technologies: Application for the discovery of drug and gene delivery agents
Adv Drug Deliv Rev
(2006) - et al.
Inserting foreign peptides into the major coat protein of bacteriophage M13
FEBS Lett
(1992) - et al.
Improved transfection of spleen-derived antigen-presenting cells in culture using TATp-liposomes
J Control Release
(2009) - et al.
Targeted gene delivery to mammalian cells by filamentous bacteriophage
J Mol Biol
(1999) - et al.
Polymer-based siRNA delivery: Perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery
J Control Release
(2007)
Utilizing RNA interference to enhance cancer drug discovery
Nat Rev Drug Discov
Translocation of liposomes into cancer cells by cellpenetrating peptides penetratin and tat: A kinetic and efficacy study
Mol Pharmacol
Targeted delivery of small interfering RNA: Approaching effective cancer therapies
Cancer Res
Cell penetrating peptides enhance intracellular translocation and function of siRNA encapsulated in Pegylated liposomes
Yao Xue Xue Bao
Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein
Nanomedicine (Lond)
Tumor targeting with a selective gelatinase inhibitor
Nat Biotech
A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery
Cancer Res
Cited by (84)
Unraveling the potential of M13 phages in biomedicine: Advancing drug nanodelivery and gene therapy
2023, Environmental ResearchViruses as biomaterials
2023, Materials Science and Engineering R: ReportsPhage for cancer therapy
2023, Progress in Molecular Biology and Translational SciencePhage for drug delivery vehicles
2023, Progress in Molecular Biology and Translational ScienceEncapsulation for breast cancer treatment
2023, Principles of Biomaterials Encapsulation: Volume 2Nanomaterials and immune system
2022, Immunomodulatory Effects of Nanomaterials: Assessment and Analysis
This work was supported by the NIH grant 1 R01 CA125063-01 and Calvert Research Institute LLC grants to Valery A. Petrenko. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of National Cancer Institute of NIH and Calvert Research Institute.
There are no disclosures or any conflicts of interest with regard to this publication.